Your browser doesn't support javascript.
loading
[Establishment of a patient-derived xenograft humanized mouse model for hepatoblastoma in children].
Hu, H M; Zhang, W L; Huang, D S; Li, R; Gu, H L; Li, J; Gao, Y N.
Afiliación
  • Hu HM; Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100176, China.
  • Zhang WL; Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100176, China.
  • Huang DS; Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100176, China.
  • Li R; Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100176, China.
  • Gu HL; Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100176, China.
  • Li J; Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100176, China.
  • Gao YN; Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100176, China.
Zhonghua Gan Zang Bing Za Zhi ; 31(10): 1075-1080, 2023 Oct 20.
Article en Zh | MEDLINE | ID: mdl-38016773
ABSTRACT

Objective:

To establish a patient-derived xenograft (PDX) humanized mouse model for hepatoblastoma in children. In addition, compare the biological consistency between successfully modeled PDX tumors and primary tumors in children while comparing and analyzing the influence of PDX model modeling success as a key factor.

Methods:

A PDX tumor model was constructed from fresh tumor tissue samples from 39 children with hepatoblastoma. The tumor growth time and volume size were recorded in detail. Simultaneously, 39 children's data were collected for experimental and clinical analysis. The difference in tumorigenesis rate between different parameters was analyzed by χ (2) test (categorical variable). Continuous variables with a normal distribution were compared using the t-test.

Results:

After cell passage and pathological diagnosis, 21 cases of hepatoblastoma PDX models were successfully constructed, with a success rate of 53.8% (21/39). Tumor samples from each generation of successfully modeled PDX models had pathology results that were consistent with those of the corresponding primary tumors. The analysis of the key factors affecting the tumor formation rate of PDX revealed that the metastasis rate was more successful in primary tumors than in liver in situ tumors (7/8 vs. 14/31, P = 0.049). However, there was no significant difference between tumor formation rates and pathological subtypes. According to the PDX tumor formation group comparison between the primary tumor and the metastatic tumor, there was no statistically significant difference between the two groups in terms of tumor formation time and tumor volume. Hematoxylin-eosin staining in hepatoblastoma's PDX mouse was consistent with the primary tumor. Immunohistochemistry positivity rates of four proteins, namely hepatocyte antigen (Hepatocyte), phosphatidylinositol glycan 3, ß-catenin, and alpha-fetoprotein, in primary tumor tissues and PDX mouse models were 100% vs. 100%, 100% vs. 95.24%, 100% vs. 100%, and 95.24% vs. 85.71%, respectively.

Conclusion:

A PDX mouse model for hepatoblastoma has been successfully established in children. The tumor formation rate is high, with metastatic tumors having a higher tumor formation rate than primary tumors and transplanted tumors retaining the biological characteristics of primary tumors.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hepatoblastoma / Neoplasias Hepáticas Límite: Animals / Child / Humans Idioma: Zh Revista: Zhonghua Gan Zang Bing Za Zhi Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hepatoblastoma / Neoplasias Hepáticas Límite: Animals / Child / Humans Idioma: Zh Revista: Zhonghua Gan Zang Bing Za Zhi Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China